REGULATORY

Xolair Faces New Special Re-Pricing Rule; Keytruda, Lixiana Caught by Huge-Seller Price Slash

January 21, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Novartis Pharma’s asthma drug Xolair (omalizumab) will become the first drug to face a new special re-pricing rule to be introduced in April after its label expansion to pollen allergy last December, while MSD’s I/O star Keytruda (pembrolizumab) will get…

To read the full story

Xolair Faces 37.3% Price Slash, Keytruda 20.9% in April: MHLW
March 5, 2020
Xolair’s Re-Pricing Decided, but Regulators and Novartis Were at Odds over Patient Projections
March 2, 2020
Japan’s Special Re-Pricing Rules to Hit 17 Drugs in April; Potentially Big Slash for Keytruda, Lixiana
January 22, 2020

REGULATORY

Ishin Proposes Adding Drug, Device Makers to Chuikyo, LDP Wary
June 10, 2026
Cabinet Approves Immunization Act Revision to Cover Antibody Drugs
June 10, 2026
LDP Lawmakers Seek Routine HPV Vaccinations for Males by April 2027
June 10, 2026
LDP Team Seeks Minister-Led AI Task Force at MHLW
June 10, 2026
MHLW to Continue Reviewing Tavneos Safety Measures: Official
June 10, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

20 Years at a Glance: Overseas Sales Surge at Japan Pharma, but R&D Investments Lag

By Hayate Horiguchi

Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…